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Abstract
Objective To provide an accurate assessment of complications of
pregnancy in women with chronic hypertension, including comparison
with population pregnancy data (US) to inform pre-pregnancy and
antenatal management strategies.
Design Systematic review and meta-analysis.
Data sources Embase, Medline, and Web of Science were searched
without language restrictions, from first publication until June 2013; the
bibliographies of relevant articles and reviews were hand searched for
additional reports.
Study selection Studies involving pregnant women with chronic
hypertension, including retrospective and prospective cohorts, population
studies, and appropriate arms of randomised controlled trials, were
included.
Data extraction Pooled incidence for each pregnancy outcome was
reported and, for US studies, compared with US general population
incidence from the National Vital Statistics Report (2006).
Results 55 eligible studies were identified, encompassing 795 221
pregnancies. Women with chronic hypertension had high pooled
incidences of superimposed pre-eclampsia (25.9%, 95% confidence
interval 21.0% to 31.5 %), caesarean section (41.4%, 35.5% to 47.7%),
preterm delivery <37 weeks’ gestation (28.1% (22.6 to 34.4%), birth
weight <2500 g (16.9%, 13.1% to 21.5%), neonatal unit admission
(20.5%, 15.7% to 26.4%), and perinatal death (4.0%, 2.9% to 5.4%).
However, considerable heterogeneity existed in the reported incidence
of all outcomes (τ2=0.286-0.766), with a substantial range of incidences
in individual studies around these averages; additional meta-regression
did not identify any influential demographic factors. The incidences (the
meta-analysis average from US studies) of adverse outcomes in women
with chronic hypertension were compared with women from the US
national population dataset and showed higher risks in those with chronic
hypertension: relative risks were 7.7 (95% confidence interval 5.7 to
10.1) for superimposed pre-eclampsia compared with pre-eclampsia,
1.3 (1.1 to 1.5) for caesarean section, 2.7 (1.9 to 3.6) for preterm delivery
<37 weeks’ gestation, 2.7 (1.9 to 3.8) for birth weight <2500 g, 3.2 (2.2
to 4.4) for neonatal unit admission, and 4.2 (2.7 to 6.5) for perinatal
death.
Conclusions This systematic review, reporting meta-analysed data
from studies of pregnant women with chronic hypertension, shows that
adverse outcomes of pregnancy are common and emphasises a need
for heightened antenatal surveillance. A consistent strategy to study
women with chronic hypertension is needed, as previous study designs
have been diverse. These findings should inform counselling and
contribute to optimisation of maternal health, drug treatment, and
pre-pregnancy management in women affected by chronic hypertension.
Introduction
Chronic hypertension complicates between 1% and 5% of
pregnancies,1-4 but this estimate is drawn from a small number
of population based studies, including publications from more
than 20 years ago. Recent demographic changes in the antenatal
population suggest that chronic hypertension in pregnancy may
be an increasing clinical problem. In populations in which
maternal age at childbirth is increasing, the association of
hypertension with advancing age will inevitably contribute to
a greater prevalence of chronic hypertension.5 In the United
States, for example, chronic hypertension is likely to have
paralleled the increase in first deliveries in women aged over
35 years from 1% to 8% that occurred between 1970 and 2006.6
Maternal age may not be the only factor; a recent population
based study in the United States suggests that the prevalence of
chronic hypertension in pregnancy increased between 1995-96
and 2007-08, despite adjustment for maternal age.4 An increase
in other risk factors for chronic hypertension, including obesity
and the metabolic syndrome, is likely to contribute.7 8 Globally,
therefore, the number of women entering pregnancy with
established chronic hypertension is set to rise.9
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Chronic hypertension is associated with poor outcomes of
pregnancy.10Numerous case-control studies frequently identify
chronic hypertension as a risk factor for most known adverse
events for mother and fetus.11-13 Retrospective and prospective
cohort studies, intervention trials, and observational studies for
high risk pregnancies similarly document higher rates of
complications of pregnancy in women with chronic
hypertension.8 14-16 Individually, these reports, usually from
single centre studies, provide valuable data for a given
population, but they are of limited use for wider extrapolation.
Nevertheless, collectively, they may enable accurate assessment
of pregnancy outcomes in affected women.
Primary and secondary healthcare professionals involved in the
management of women of childbearing age with chronic
hypertension include family doctors, clinical pharmacologists,
cardiologists, nephrologists, endocrinologists, and general
physicians. All may be called on to provide information for
women planning a pregnancy. Pregnancy is frequently the first
time when chronic hypertension is identified by midwives and
obstetricians.17 In the absence of a strong evidence base for
accurate risk assessment in chronic hypertension, providing
useful estimates of adverse pregnancy outcomes presents a
challenge. The objective of this study was to conduct a
meta-analysis of population based, multicentre, and single centre
studies, to provide a reliable assessment of risks of pregnancy
in womenwith chronic hypertension, drawing comparison with
outcomes available from US studies and the US general
population (2006) of pregnant women.
Methods
Literature review
We did a comprehensive literature review using the databases
PubMed/Medline (via OVID), Embase (via OVID), and Web
of Science. We tailored search strategies to each database. We
used MeSH and free text terms in conjunction to increase
sensitivity to potentially appropriate studies.WhereMeSH terms
were not used (Web of Science), we identified search terms and
all possible synonyms and spellings obtained and used them in
the search strategy. In Web of Science, we selected the
“lemmatisation” option.We searched pregnancy complications
and outcomes terms and chronic hypertension terms separately,
and then combined them in each database. The study protocol
is provided in supplementary information 1. We applied no
limits other than the search strategy to databases. We searched
databases from the time of first publication (Medline 1946,
Embase 1947, Web of Science 1899) until June 2013.
Study selection criteria
We included prospective and retrospective cohort studies. We
reviewed randomised controlled trials, excluding the treatment
arm if a difference existed in outcomes and including both arms
if no benefit of the intervention was seen. We excluded
case-control studies, case reports, reviews, letters to editors, and
animal/in vitro studies.
To minimise selection bias, we did not include studies that
excluded women with superimposed pre-eclampsia or
categorisedwomenwith chronic hypertension and superimposed
pre-eclampsia together with low risk womenwith pre-eclampsia,
as this was one of the outcomes of interest. We considered
studies with fewer than 20 women with chronic hypertension
to be non-representative, and we excluded studies that did not
report relevant outcome data.
Data extraction
KB and BP independently reviewed abstracts and full texts, and
LC reviewed any discrepancies. The same authors independently
extracted and tabulated data from selected full texts. When two
studies included the same cohort, we included only the report
with the largest number of women or most relevant outcomes.
We followed PRISMA guidelines for all procedures and
reporting.18We used the Newcastle-Ottawa scale to grade cohort
studies. We considered multi-fetal gestations as one pregnancy
for maternal outcomes and two pregnancies for fetal outcomes.
We recorded details of other potential confounders and
adjustments, including age, secondary hypertension, body mass
index, weight, parity, smoking, and ethnicity. Manuscripts not
published in English were translated by native speaking
physicians. We included abstracts if a definition of chronic
hypertension and relevant outcomes were described.
We examined and reported definitions of chronic hypertension
and superimposed pre-eclampsia (when available) for each
included study. For purposes of analysis, we used the following
definitions: preterm delivery—delivery before 37 weeks’
gestation (up to 36+6); low birth weight—below 2500 g; perinatal
death—fetal death after 20 weeks’ gestation including stillbirth
and neonatal death up to 1 month; neonatal unit
admission—admission to neonatal intensive care or special care
baby unit.
Statistical analysis
We used mixed effects logistic regression for meta-analysis,
using the Stata command “xtmelogit.” We used extracted data
to calculate estimated pooled incidences, 95% confidence
intervals, and predicted 95% incidence ranges (prediction
intervals) of adverse outcomes. Prediction intervals have been
proposed as being akin to a reference range for that parameter
across the population, allowing more appropriate interpretation
and extrapolation into clinical practice.19 Ninety five per cent
prediction intervals show the uncertainty of the range of possible
percentage incidences for a new study population, whereas 95%
confidence intervals show the uncertainty about the estimate of
the average percentage incidence across study populations.
We used mixed effects logistic regression, which allows for
random variation at more than one level, on the assumption that
significant heterogeneity would exist both between individuals
and between studies and that each study would be likely to
include covariates that could influence outcomes. We used the
τ2 statistic to describe heterogeneity and did subgroup analyses
according to seven groupings selected before analysis: country’s
economic wealth according toWorld Bank classification (gross
national income per capita),20 study period, inclusion or
exclusion of multiple pregnancies, inclusion or exclusion of
congenital abnormalities, inclusion or exclusion of women with
secondary hypertension, study design, and study definition of
chronic hypertension. We also stratified studies reporting
incidences of superimposed pre-eclampsia according to the
study definition of superimposed pre-eclampsia.We used forest
plots to assess overall effect. We calculated risk ratios for US
studies relative to separate comparator data obtained from the
Centers for Disease Control and Prevention’s vital statistics
2006 (US national statistics) for pooled incidences and for
individual study outcomes.21
We also did meta-regression using “xtmelogit” regression to
identify the influence of potential modifiers of outcome
including parity, maternal age, and ethnicity on the relation
between chronic hypertension and subsequent outcome. As
individual level data were unavailable, we used aggregate data
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for each study (mean and standard deviation for age, and
proportions of nulliparous/multiparous and white/non-white
women).Wemade estimates of mean age if categories of ranges
were presented. We used Stata version 11 for all statistical
analyses, and all tests and confidence intervals were two sided
with a significance level of 0.05.
Results
Figure 1⇓ shows the study selection process. Following
title/abstract screening, 208 papers remained for full text review.
Four abstracts were unavailable for analysis despite repeated
attempts to contact the authors. Fifty five studies, comprising
795 221 pregnancies and 812 772 infants, met inclusion criteria
and are reported in tables 1⇓, 2⇓, 3⇓, and 4⇓.15 16 22-74 All studies
achieved a total Newcastle-Ottawa grading score of 5 to 7, and
no studies were excluded following grading. Newcastle-Ottawa
gradings are shown in supplementary information 2.
Five studies were randomised controlled trials, including a
primary analysis,16 three secondary analyses of studies that did
not have differences between treatment and placebo arms,15 22 24
and one study that reported a difference in outcomes between
the treatment (L-arginine supplementation) and placebo arm,23
so only the placebo arm was included. One study included both
prospective and retrospective data and was categorised as
retrospective as this was the larger group.32
Maternal demographics of women with chronic hypertension,
if reported, are shown in online supplementary information 2.
Individual study definitions of chronic hypertension and
categories according to definition are shown in tables 1⇓, 2⇓,
3⇓, and 4⇓ and in more detail in online supplementary
information 3. Study definitions for superimposed pre-eclampsia
are shown in online supplementary information 4. Table 5⇓
shows pooled incidences and prediction intervals of adverse
pregnancy outcomes. Table 6⇓ shows risk ratios of adverse
pregnancy outcomes from US studies compared with US
population data.
The relative risk of superimposed pre-eclampsia in women with
chronic hypertension was on average across study populations
nearly eightfold higher than was pre-eclampsia in the general
pregnancy population, and all adverse neonatal outcomes were
at least twice as likely to occur compared with the general
population.
The meta-analysis summary results and 95% confidence
intervals relate to the average percentage incidence across
studies. However, heterogeneity existed in most analyses, as
seen by τ2 values above zero. Thus genuine variation in
incidences exists across study populations; in other words, in
some populations the true incidence is well above the average,
and in others it is well below the average. This is shown by wide
95% prediction intervals for the potential percentage incidence
in a new study population. Only the limits of the prediction
interval for superimposed pre-eclampsia excluded the US
national data incidence of pre-eclampsia, which shows that the
increased rate was evident across the different settings of the
studies.
Figures 2⇓, 3⇓, 4⇓, 5⇓, 6⇓, and 7⇓ show forest plots for the
pooled incidence of superimposed pre-eclampsia, caesarean
section, preterm delivery before 37 weeks’ gestation, birth
weight <2500 g, perinatal death, and neonatal unit admission.
Heterogeneity of incidence of superimposed pre-eclampsia
seemed to be lower in randomised controlled trials (τ2=0.026)
than in population studies (τ2=0.438) and was greater in
prospective cohort (τ2=0.83) and retrospective cohort studies
(τ2=1.080). Stratification of studies according to study definitions
of superimposed pre-eclampsia did not further reduce
heterogeneity measured by τ2. The incidence of neonatal unit
admission was lower in one population study (7.1%, 95%
confidence interval 6.0% to 9.2%) compared with randomised
controlled trials (20.1%, 19.5% to 24.3%), but only one
population study was included in this subgroup analysis.
Further comparison of τ2 did not identify any significant
influence of multiple pregnancies, congenital abnormalities,
period of delivery, country’s economic wealth, inclusion of
secondary hypertension, maternal age, parity, ethnicity, or study
definition of chronic hypertension on the degree of heterogeneity
(τ2>0.2 for all subgroups) or proportion of women with adverse
events.
Discussion
This meta-analysis of 55 studies from 25 countries, including
795 221 pregnancies and spanning four decades, confirms that
chronic hypertension is associated with adverse pregnancy
outcomes. The pooled average incidence, across study
populations, of superimposed pre-eclampsia, caesarean section,
preterm delivery before 37 weeks’ gestation, birth weight <2500
g, perinatal death, and neonatal unit admission were all
significantly higher in US studies than the general US pregnancy
population. Moreover, for superimposed pre-eclampsia, the
limits of the 95% prediction intervals (reference range) for the
US based studies were higher than the rate of pre-eclampsia
reported in the US population. Heterogeneity between studies
existed, and 95% prediction intervals were broad. Incidences
of superimposed pre-eclampsia reported by randomised
controlled trials were less heterogeneous than for other study
designs but similar to the overall pooled incidence of
superimposed pre-eclampsia in women with chronic
hypertension. However, meta-regression did not identify any
other underlying causes of heterogeneity, suggesting that either
populations with chronic hypertension are varied or
determination of chronic hypertension and outcomes may not
be consistent.
Strengths and weaknesses of study
Studies were carefully selected according to a rigorous search
strategy to enable unbiased inclusion of retrospectively or
prospectively studied cohorts, population studies, or randomised
controlled trials. For example, superimposed pre-eclampsia has
been shown to be associated with worse pregnancy
outcomes,15 75-79 but some reports, initially assessed for the
purpose of this study, excluded women with chronic
hypertension and superimposed pre-eclampsia. This would lead
to an underestimation of other adverse events, so we did not
include these publications in the analysis. In other studies,
women with superimposed pre-eclampsia were frequently
groupedwith other womenwith pre-eclampsia alone, precluding
useful risk assessment for women with chronic hypertension.
These studies were also excluded from meta-analysis.
Despite the selection of relevant and appropriately performed
studies, we observed substantial diversity of reported incidences
of adverse outcome. This is likely to reflect variations in the
selection of women studied and difficulties of measurement but
also true differences within the population of women with
chronic hypertension. We conducted exploration to identify
important confounders, including maternal age, ethnicity,
economic wealth of country, decade of deliveries reported,
parity, inclusion of secondary hypertension, multiple pregnancies
and congenital birth defects, study design, and study definition
of chronic hypertension. Although randomised controlled trials
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were more consistent than other study designs, we found no
systematic differences in mean event rates to explain the
disparity in outcomes. Most papers did not report relevant
baseline demographics defining the population studied, which
limited the assessment of confounders. Coexisting factors
includingmaternal age and ethnicity, recognised to be associated
with both chronic hypertension and adverse pregnancy outcome,
may contribute to confounding, but their relative effects are
unknown.
Few studies in the meta-analysis reported control data, so a
direct comparison of outcomes between women with chronic
hypertension and normotensive women was not possible. To
provide clinical context and relevance, we selected US
population data (2006)21 as a separate population for comparison
against the US chronic hypertension studies, because these data
provide the most comprehensive national annual statistics.
Although US population data also report outcomes in high risk
women, including those with chronic hypertension, the
proportion of women with chronic hypertension in this dataset
is small and therefore unlikely to influence the overall incidence
of adverse outcomes. We chose the dataset from 2006 as being
sufficiently recent to be clinically relevant but not too
chronologically distant from the years in which most of the
studies were conducted.
We could not elucidate the effect of differing antihypertensive
treatments on the maternal and perinatal outcomes, as
insufficient information was provided to allow subanalysis by
drug group. This problem is made more complex by scenarios
that include changing treatment over the gestation—for example,
when a pregnant woman starts pregnancy while taking one drug,
stops all treatment during themid-trimester blood pressure nadir,
and then restarts with a different drug when her blood pressure
exceeds a certain threshold. In addition, many population based
registry studies may record prescriptions from a database, rather
than provide data that confirm that treatment has been taken.
Thus assigning an individual woman to any drug treatment is
difficult even within trimesters.
Strengths andweaknesses in relation to other
studies
To our knowledge, few other detailedmeta-analyses of outcomes
of pregnancy in women with chronic hypertension have been
reported. Population studies have reported data from large
numbers of women with chronic hypertension and can be a
useful guide to risks of pregnancy, but their generalisability is
unclear. Population studies are limited by inaccuracies of coding
collected for billing purposes and are susceptible to
under-recognition of hypertension in pregnancy and
misclassification. For example, Roberts and colleagues
compared hospital discharge and birth databases with medical
records and identified significant under-reporting of chronic
hypertension.3 Inadequacies of coding are also particularly
relevant to accurate diagnosis of pre-eclampsia.80 Women are
more likely to be reported to have chronic hypertension if it had
been recorded in an admission before pregnancy,3 suggesting
that women with more severe or longstanding chronic
hypertension may be more likely to be included in population
studies.
No threshold of blood pressure that predicts poor pregnancy
outcomes has been identified, and an association between both
systolic and diastolic blood pressure and adverse events has
been reported.81 Similarly, the length of time between diagnosis
of hypertension and pregnancy is associated with more adverse
events.24 Chronic hypertension may be undetectable in early
pregnancy owing to systemic vasodilatation and reduced
vascular resistance,82 resulting in a fall in blood pressure, so
women with a blood pressure below 140/90 mm Hg before 20
weeks’ gestation would be excluded from many of the studies
assessed, unless they were already taking antihypertensive drugs
during or before pregnancy. The identification of women with
chronic hypertension is therefore challenging, and the fact that
multiple different definitions of chronic hypertension were given
is unsurprising. This may explain some diversity in incidence
of adverse events between studies; however, categorisation of
studies according to definition of chronic hypertension did not
reduce heterogeneity between outcomes.
In keeping with the challenges of diagnosing chronic
hypertension, identification of superimposed pre-eclampsia
remains difficult, and uncertainties exist. Research definitions
have gone some way towards standardising diagnoses.83 In this
meta-analysis, 16 (30%) studies did not report diagnostic criteria,
and the remainder used 18 varying, though valid, definitions of
superimposed pre-eclampsia. Lack of consistency is likely to
affect the heterogeneity of outcomes across studies.
Although women with more severe chronic hypertension,
managed in specialist clinics, may be over-represented in some
cohort studies, pregnancy outcomes did not differ by definition
of inclusion criteria. Lack of blood pressures at first antenatal
visit or use of antihypertensive drugs in early pregnancy
precluded assessment of outcomes by severity of hypertension,
although degree of hypertension clearly affects the decision for
treatment and outcomesmay therefore be influenced by severity.
The findings of this study remain applicable to the women with
chronic hypertension most frequently encountered and most in
need of specialist advice.
Meanings of study and implications for
physicians and health providers
The most recent UK Confidential Enquiry into Maternal and
Child Health identified chronic disease as an underlying factor
in preventable maternal deaths.84 Consequently, the first
recommendation stated that “Pre-pregnancy counselling services,
. . . for women with pre-existing medical illnesses . . . are a key
part of maternity services,” supported by the National Institute
for Health and Care Excellence’s guidelines for the management
of hypertension in pregnancy.85 Furthermore, the American
Congress of Obstetricians and Gynecologists’ recent practice
bulletin recommends that women with chronic hypertension
“should be evaluated before conception to ascertain possible
end-organ involvement.”86 Systematic reviews andmeta-analyses
can provide data more readily inferable to the individual, but
no large aggregate analysis of pregnancy outcome in women
with chronic hypertension has previously been reported. This
meta-analysis of outcomes can be used before pregnancy and
antenatally by healthcare professionals (including those not
providing direct maternity care) advising women with chronic
hypertension regarding possible adverse pregnancy events.
Accessibility to healthcare professionals and facilitation of early
referral will allow drug treatment to be optimised on an
individual basis (for example, starting aspirin and planning a
change from cardio-renoprotective angiotensin converting
enzyme inhibitors and angiotensin-II receptor blockers to
alternative non-teratogenic antihypertensive drugs at the first
positive pregnancy test or pre-pregnancy) or enable reassurance
regarding continuation of drugs that are safe in pregnancy, to
reduce the risk of complications including cerebrovascular
events.
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Debate is ongoing as to how antihypertensive treatment
influences outcomes. Although reasonable evidence from a
Cochrane systematic review shows that use of antihypertensive
drugs halves the incidence of severe hypertension, it has not
been shown to affect any other outcomes, including risk of
pre-eclampsia, perinatal death, preterm birth, or small for
gestational age babies.87 Recent work has found that the risk of
certain malformations such as congenital heart disease is similar
in women taking angiotensin converting enzyme inhibitors and
those with underlying hypertension taking no treatment, both
having increased risk compared with normotensive controls,
suggesting that the hypertension itself may contribute to
congenital malformations.88 Systematic reviews have also
identified that a greater mean difference inmean arterial pressure
with antihypertensive treatment is associated with the birth of
a higher proportion of small for gestational age infants,89
providing the basis for the Chronic Hypertension In Pregnancy
Study (CHIPS). This study, which has recently completed
recruitment of more than 1000 women with hypertension in
pregnancy, but is yet to report, was designed to determine
whether tight or less tight blood pressure control influences the
likelihood of pregnancy loss or neonatal intensive care unit
admission.90 A recent study showing that women with chronic
hypertension taking antihypertensive drugs have worse perinatal
outcomes than do those not on treatment was unable to adjust
for severity of underlying hypertension and indicates the need
for future prospective studies to explore the influence of
pre-existing disease severity.91
While the debate on the use and type of antihypertensive drugs
continues, other beneficial management strategies needing
implementation before or in early pregnancy include lifestyle
adjustments (such as weight loss).92 Our group has previously
shown that women with chronic hypertension who continue to
smoke in pregnancy are at greater risk of superimposed
pre-eclampsia (compared with non-smokers), so smoking
cessation is also an essential component of counselling.
Future research
Increasing numbers of pregnancies will be complicated by
chronic hypertension as the trend continues for women to delay
conception, together with the global epidemic of obesity. The
consequences of complicated pregnancy outcome are not only
costly in the short term, but the long term health consequence
for the offspring of women with chronic hypertension and the
subsequent financial burden should be acknowledged.93 The
findings of this meta-analysis support the need for improved
understanding of the pathophysiology of chronic hypertension,
to inform the development of predictive and diagnostic tools
and enhance therapeutic interventions to reduce adverse
pregnancy outcomes. The continuing uncertainty about maternal
and perinatal effects of antihypertensive treatment shows the
need for large observational studies (for example, through
population registers) and randomised controlled trials of drug
treatment in women with chronic hypertension, to determine
optimal management for mother and fetus. As severity of
hypertension will always confound need for treatment and
perinatal outcomes, this must be considered for appropriate
conclusions to be drawn.
Conclusions
Chronic hypertension is associated with a high incidence of
adverse pregnancy outcomes compared with a general
population, as exemplified in this report by US data. This finding
should be interpreted within the limitations of the study. Our
results support the importance of increased antenatal surveillance
for women with chronic hypertension to enable early
identification of evolving complications.Women should receive
pre-pregnancy counselling to optimise their health before
pregnancy and to inform them of the increased maternal and
fetal risks associated with their hypertension. Strategies to
predict those at greatest risk, determine optimal drug treatments,
and reduce adverse pregnancy outcomes are needed.
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Tables
Table 1| Overview of randomised controlled trials of pregnancy outcomes in women with chronic hypertension included in meta-analysis
Newcastle-Ottowa
grade
Definition of
chronic
hypertension*
Congenital
abnormalities
excluded
Secondary causes of
chronic hypertension
excluded
Multiple
gestations
included
No of
births
No of
womenCountryStudy years
Author, year
published
73NoCreatinine >1.2 mg/dL
excluded
No110110USA2003August et al,
200422
72NoNoNo822822UK and
Netherlands
2003-05Chappell et al,
200815
61YesKnown cardiac or renal
disease excluded
No4040Italy2006-08Neri et al, 201023
74NoType 1 diabetes
excluded
No763763USA?-1998Sibai et al,
199824
62NoNo evidence of
proteinuria (24 hour
urine protein <100mg)
No2525USA?-1986Weitz et al,
198716
*1=systolic blood pressure >140 or diastolic blood pressure >90 mm Hg and/or history of hypertension; 2=diastolic blood pressure >90 mm Hg and/or history of
hypertension; 3=history of hypertension before pregnancy or presence of hypertension before 20 weeks with no blood pressure definition; 4=blood pressure
>140/90 mm Hg; 5=history of hypertension only; 6=antihypertensive drug treatment before 20 weeks; 7=other.
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Table 2| Overview of population studies of pregnancy outcomes in women with chronic hypertension included in meta-analysis
Newcastle-Ottowa
grade
Definition of
chronic
hypertension*
Congenital
abnormalities
excluded
Secondary causes
of chronic
hypertension
excluded
Multiple
gestations
included
No of
births
No of
womenCountryStudy years
Author, year
published
73YesNoYes12581242Canada1988-2000Allen et al, 200425
75NoPrimary and
secondary defined
Yes750 078731 694 (649
899 primary,
81 795
secondary)
USA1995-2008Bateman et al,
201226
62Yes“Relevant
comorbidity
excluded”
No16091609Netherlands2002-07Broekhuijsen et
al, 201227
74NoWomen with renal
disease, cardiac
disease, diabetes
mellitus excluded
No11161116Norway1999-2002Rasmussen et al,
200628
72NoNoNo21622162Australia2000-02Roberts et al,
200529
72NoNoNo27272727Taiwan2005Su et al, 201330
71NoNoNo47494749Sweden1992-2004Zetterstrom et al,
200831
*1=systolic blood pressure >140 or diastolic blood pressure >90 mm Hg and/or history of hypertension; 2=diastolic blood pressure >90 mm Hg and/or history of
hypertension; 3=history of hypertension before pregnancy or presence of hypertension before 20 weeks with no blood pressure definition; 4=blood pressure
>140/90 mm Hg; 5=history of hypertension only; 6=antihypertensive drug treatment before 20 weeks; 7=other.
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Table 3| Overview of prospective studies of pregnancy outcomes in women with chronic hypertension included in meta-analysis
Newcastle-Ottowa
grade
Definition of
chronic
hypertension*
Congenital
abnormalities
excluded
Secondary causes
of chronic
hypertension
excluded
Multiple
gestations
included
No of
births
No of
womenCountryStudy years
Author, year
published
72NoCardiac or renal
disease excluded
No6464Benin1995-96Attolou et al, 199832
61No“No diabetes, cardiac
or renal disease”
Yes7266USA1973-79Curet et al, 197933
61NoNoNo5555USA1982-84Fleischer et al,
198634
63No“Essential
hypertension only”
No6363USA?-1977Gant et al, 197735
71NoNoNo396396Finland1985-86Hartikainen et al,
199836
61No“Mild chronic
hypertension without
other disease”
No110110Mexico2001-07Inigo Riesgo et al,
200837
71NoNoNo23932393Belgium2001-02Jacquemyn et al,
200638
62NoNoYes169156USA1980-84Mabie et al, 198639
62No“Free of major
diseases such as
diabetes mellitus,
sickle cell anaemia,
renal failure and heart
disease”
No2020Nigeria1992-94Onyiriuka andOkolo,
200540
71NoNoNo459459Canada1986-95Ray, 200141
71NoNoUnknownUnknown298Canada1987-91Rey and Couturier,
199442
71NoRenal disease and
pre-pregnancy
diabetes excluded
Yes208208USA1987-91Rey, 199743
71YesExcluded proteinuria
at first visit
No182182Italy2000-06Roncaglia et al,
200844
75NoNoNo6666Mexico1996-97Ruiz et al, 200145
61NoNoNo131131USA1995-2001Segel et al, 200146
66NoNoNo215211USA1980-82Sibai et al, 198347
66NoNoNo4444USA1978-84Sibai et al, 198648
72NoNoNo121121China2001-05Sun et al, 200749
63NoNoNo2626Italy1993-96Valsecchi et al,
199950
62NoNoNo8787USA1999-2002Zeeman et al, 200451
*1=systolic blood pressure >140 or diastolic blood pressure >90 mm Hg and/or history of hypertension; 2=diastolic blood pressure >90 mm Hg and/or history of
hypertension; 3=history of hypertension before pregnancy or presence of hypertension before 20 weeks with no blood pressure definition; 4=blood pressure
>140/90 mm Hg; 5=history of hypertension only; 6=antihypertensive drug treatment before 20 weeks; 7=other.
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Table 4| Overview of retrospective studies of pregnancy outcomes in women with chronic hypertension included in meta-analysis
Newcastle-Ottowa
grade
Definition of
chronic
hypertension*
Congenital
abnormalities
excluded
Secondary causes
of chronic
hypertension
excluded
Multiple
gestations
included
No of
births
No of
womenCountryStudy years
Author, year
published
62NoNoYes3130USA1981Ales et al, 198952
67NoNoNo7272India1995-2004Bagga et al, 200753
62Yes“Secondary
hypertension
excluded”
Yes16271579Hungary1980-96Banhidy et al, 201054
51NoNoNo447447Spain1984Comino-Delado et al,
198655
71NoNoYes210210Croatia1987-90Delmis et al, 199356
63NoNoNo210210Italy1986-95Ferrazzani et al,
201157
61NoNoNo5252Israel1990-92Fields et al, 199658
77YesNo proteinuria at
entry or secondary
hypertension
No7878Italy1993-95Frusca et al, 199859
72NoNoYes29 91729 842USA1991-2001Gilbert et al, 200760
63NoNoNo20482048USA1982-87Jain, 199761
66YesSecondary
hypertension
excluded
No211211France2004-07Lecarpentier, 201362
51NoDiabetes, renal
disease, secondary
forms of
hypertension
excluded
No213152UK1980-97Lydakis et al, 199863
61NoNoYes9897Portugal1988-92Machado et al,
199664
71NoSecondary
hypertension
excluded
No120120Japan2006-09Ono et al, 201365
71YesSecondary
hypertension
excluded
No7070USA1992-95Parry et al, 199866
61NoNoNo109109USA1987Pietrantoni et al,
199467
61NoNoNo189189Brazil1985-86Sass et al, 199068
72YesNoNo10321032USA1990-2008Tuuli et al, 201169
72NoNoNo18071807Israel1988-99Vanek et al, 200470
73NoNot complicated by
cardiac disease,
renal disease,
diabetes mellitus
No40144014USA?-1994Velentgas et al,
199471
67NoNoYes157154Panama1996-2001Vigi-De-Gracia et al,
200472
65NoNoNo165165USA2008-10Wilson et al, 201273
62NoNoNo117117USA?-2003Zeeman et al, 200374
*1=systolic blood pressure >140 or diastolic blood pressure >90 mm Hg and/or history of hypertension; 2=diastolic blood pressure >90 mm Hg and/or history of
hypertension; 3=history of hypertension before pregnancy or presence of hypertension before 20 weeks with no blood pressure definition; 4=blood pressure
>140/90 mm Hg; 5=history of hypertension only; 6=antihypertensive drug treatment before 20 weeks; 7=other.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2014;348:g2301 doi: 10.1136/bmj.g2301 (Published 15 April 2014) Page 11 of 20
RESEARCH
 o
n
 8 July 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.g2301 on 15 April 2014. Downloaded from 
Table 5| Estimated incidence and prediction intervals of adverse pregnancy outcomes for women with chronic hypertension
Heterogeneity τ2Prediction intervals (95%)Estimated incidence (%) (95% CI)No of studiesOutcome
0.7665.5 to 67.225.9 (21.0 to 31.5)38Superimposed pre-eclampsia
0.41315.5 to 73.241.4 (35.5 to 47.7)27Caesarean section
0.2866.8 to 67.628.1 (22.6 to 34.4)30Pre-term delivery (<37 weeks)
0.2865.7 to 40.616.9 (13.1 to 21.5)14Birth weight <2500 g
0.4035.9 to 51.320.5 (15.7 to 26.4)16Neonatal intensive care
0.5440.9 to 16.44.0 (2.9 to 5.4)27Perinatal death
95% prediction intervals show uncertainty of range of possible incidence percentages for new study population, whereas 95% confidence intervals show uncertainty
about estimate of average percentage incidence across study populations.
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Table 6| Estimated incidence and prediction intervals of adverse pregnancy outcomes for women with chronic hypertension: studies
conducted in United States compared with US general population data21
Heterogeneity τ2Risk ratio (95% CI)
US general
population
incidence (%)
Prediction interval
(95%)
Estimated incidence (%)
(95% CI)No of studiesOutcome
0.6237.7 (5.7 to 10.1)3.86.6 to 70.329.2 (21.6 to 38.2)38Superimposed
pre-eclampsia
0.2581.3 (1.1 to 1.5)32.918.4 to 70.742.4 (35.0 to 50.1)27Caesarean section
0.5262.7 (1.9 to 3.6)12.27.8 to 74.133.0 (23.7 to 44.0)30Pre-term delivery (<37
weeks)
0.2252.7 (1.9 to 3.8)8.25.1 to 60.522.2 (15.4 to 30.9)14Birth weight <2500 g
0.2463.2 (2.2 to 4.4)6.15.0 to 51.919.3 (13.4 to 27.0)16Neonatal intensive care
0.4294.2 (2.7 to 6.5)1.11.0 to 18.94.6 (3.0 to 7.1)27Perinatal death
95% prediction intervals show uncertainty of range of possible incidence percentages for new study population, whereas 95% confidence intervals show uncertainty
about estimate of average percentage incidence across study populations.
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Figures
Fig 1 Flow chart of study selection process
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Fig 2 Forest plot of studies of superimposed pre-eclampsia in women with chronic hypertension stratified according to study
design. MELR=mixed effects logistic regression
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Fig 3 Forest plot of studies of caesarean section in women with chronic hypertension stratified according to study design.
MELR=mixed effects logistic regression
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Fig 4 Forest plot of studies of preterm delivery before 37 weeks’ gestation in women with chronic hypertension stratified
according to study design. MELR=mixed effects logistic regression
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Fig 5 Forest plot of studies of birth weight <2500 g in women with chronic hypertension stratified according to study design.
MELR=mixed effects logistic regression
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Fig 6 Forest plot of studies of neonatal unit admission in women with chronic hypertension stratified according to study
design. MELR=mixed effects logistic regression
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Fig 7 Forest plot of studies of perinatal death in women with chronic hypertension stratified according to study design.
MELR=mixed effects logistic regression
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